Author
By Bob Bohrer[Cross-posted on Pharmaceutical Policy.] According to a story by Bronwyn Mixter in Bloomberg’s BNA BIOTECH WATCH, the FDA has received at least twenty-five IND’s for biosimilar development programs. Some quick perspective on that is…
By Bob Bohrer I have previously posted on pharmaceuticalpolicy.blogspot.com about the FDA’s proposed change to the rules for generic drug labels and an estimate of the liability costs that might be incurred by the generic…
By Bob Bohrer An interesting development, reported in FiercePharma and originally by Reuters, on litigation between AbbVie and GlaxoSmithKline over AbbVie’s price increases on one of its combination drugs for HIV– the FiercePharma link is…
By Bob Bohrer Cross-post from Pharmaceutical Policy After last week’s foray into patents and pharmaceutical policy, which is perhaps the most technical and specialized area of pharmaceutical policy, I will return to the never-ending story…
By Bob Bohrer Cross-post from Pharmaceutical Policy There were two stories in The New York Times that, although not directly related, are the basis for today’s post. The first, by Andrew Ross Sorkin, Do Drug Companies Make Drugs,…
